Muhamed Baljevic, MD

• Multiple Myeloma

Muhamed Baljevic, MD, FACP, is a hematologist and medical oncologist who joined Vanderbilt University Medical Center as faculty in the Department of Medicine in 2021. He is the director of plasma cell disorders research and Vanderbilt amyloidosis multidisciplinary (VAMP) programs, and also serves as disease team lead for plasma cell dyscrasias and lymphomas. His clinical and research interests are in the field of multiple myeloma (MM), AL Amyloidosis and other plasma cell disorders. His investigative focus is on better understanding of mechanisms of proteasome inhibitor resistance, the importance of augmented post-transplant immune reconstitution in transplant recipients, and the role genomic events such as chromosomal alterations and gene mutations play in the transformation of premalignant plasma cell conditions to plasma cell malignant states. As institutional cellular therapy investigator in plasma cell malignancies, he aims to explore novel mechanistic approaches in the treatment of high unmet needs in relapsed and refractory MM and AL Amyloidosis, including those patients with multi-class resistant or refractory disease. Some of his recent recognitions include 2014 Celgene Future Leaders in Hematology Award for Clinical Research, and the 2015 ASCO/AACR Workshop on Methods in Clinical Cancer Research. He is the author of several dozen publications and book chapters on various hematologic malignancies.  In addition to fluent English, he is also fluent in languages of the Balkans, including his native Bosnian.